Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

SAGE® Labs, Ekam Imaging, Inc. Partner on Preclinical Imaging Assays

Published: Friday, October 19, 2012
Last Updated: Friday, October 19, 2012
Bookmark and Share
Companies to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam's expertise in functional magnetic resonance imaging (fMRI) technology.

Unlike the fMRI studies currently performed in drug development that require anesthetized, unconscious animals, Ekam Imaging's fMRI translational technology produces detailed maps of a conscious animal's brain activity, a state that much better represents the human condition.

"The rat models created by SAGE Labs have been genetically modified to reflect patient-relevant mutations and exhibit highly relevant, robust phenotypes. The combination of these rats with Ekam's imaging platform presents a transformative opportunity for translational neuroscience programs. Ultimately, these types of studies will lead to better drugs targeting neurodegenerative diseases such as Parkinson's and Alzheimer's diseases," said Edward Weinstein, Ph.D., Director of SAGE Labs.

"Probing the brain functions of a conscious animal, specifically in rats which are prized by the neuroscience community for intelligence and complex social behaviors, produces data that is much more representative of a potential therapy's effects on human processes," said Mark Nedelman, MS, MBA, President and CEO of Ekam Imaging.

Nedelman's company is currently producing a detailed map of neural activity in SAGE Lab's Pink1 gene knockout rat, which SAGE Labs generated for The Michael J. Fox Foundation to model Parkinson's disease. The Pink1 gene knockout rat exhibits delayed-onset motor deficits, a key phenotype of Parkinson's disease in humans.

Sigma and Ekam plan to publicly launch services specific to SAGE Labs' neuroscience rat models in early 2013.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sigma-Aldrich to Acquire BioReliance
Sigma-Aldrich Corporation has signed an agreement to acquire BioReliance Holdings, Inc. from Avista Capital Partners for $350 million in cash.
Tuesday, January 10, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Towards Patient-Specific Drug Screening
A new breakthrough by the 3D stem cell printing team at Heriot-Watt could pave the way to individually tailored drug testing regimes, both reducing the need for animal testing and ensuring that patients receive drugs which are most effective for their individual needs.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
Manipulating microbes maximizes tumor immunity in mice.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos